Mobile Lads Corp. (MOBO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 484.23 Thousand USD | -35.45% |
| 2021 | 750.17 Thousand USD | 15.13% |
| 2020 | 651.57 Thousand USD | 6.12% |
| 2019 | 613.97 Thousand USD | 0.0% |
| 2016 | -86.57 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -6900.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 485.03 Thousand USD | 0.16% |
| 2023 Q2 | 484.48 Thousand USD | -0.11% |
| 2022 Q3 | 484.23 Thousand USD | -1.75% |
| 2022 FY | 484.23 Thousand USD | -35.45% |
| 2022 Q1 | 514.09 Thousand USD | 0.0% |
| 2022 Q4 | 484.26 Thousand USD | 0.01% |
| 2022 Q2 | 492.84 Thousand USD | -4.13% |
| 2021 FY | 750.17 Thousand USD | 15.13% |
| 2020 FY | 651.57 Thousand USD | 6.12% |
| 2019 FY | 613.97 Thousand USD | 0.0% |
| 2017 Q1 | 3957.00 USD | 104.57% |
| 2016 Q3 | 154.57 Thousand USD | 423.65% |
| 2016 Q1 | -311.00 USD | 0.0% |
| 2016 FY | -86.57 Thousand USD | 0.0% |
| 2016 Q2 | -47.76 Thousand USD | -15257.23% |
| 2016 Q4 | -86.57 Thousand USD | -156.01% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 100.0% |
| 2014 Q3 | -3380.00 USD | 84.24% |
| 2014 Q2 | -21.45 Thousand USD | -1984.55% |
| 2014 FY | - USD | 100.0% |
| 2014 Q1 | -1029.00 USD | 0.0% |
| 2013 FY | -6900.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 37064.275% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 91.427% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 98.868% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 293.988% |
| Rebus Holdings, Inc. | 305 Thousand USD | -58.765% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 107.681% |
| Qrons Inc. | 351.42 Thousand USD | -37.79% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 22.195% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.885% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 2472.756% |
| Skye Bioscience, Inc. | -5.72 Million USD | 108.464% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 96.928% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 88.241% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -20.501% |
| SQZ Biotechnologies Company | -36.23 Million USD | 101.336% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 78.404% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 47.774% |
| Mesoblast Limited | 55.85 Million USD | 99.133% |
| Marizyme, Inc. | 18.56 Million USD | 97.392% |
| Genus plc | 190.6 Million USD | 99.746% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 78.342% |
| Pharming Group N.V. | 109.8 Million USD | 99.559% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 43.71% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 60.109% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 28.789% |
| ContraFect Corporation | -6.02 Million USD | 108.036% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -259.652% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 58.091% |
| IMV Inc. | 7.67 Million USD | 93.687% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 91.199% |
| MultiCell Technologies, Inc. | 90.04 USD | -537696.535% |
| ONE Bio Corp. | 9.04 Million USD | 94.643% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 165.974% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 96.26% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 64.602% |
| Q BioMed Inc. | 4.06 Million USD | 88.073% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 98.415% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 51.948% |
| Biomind Labs Inc. | 711.4 Thousand USD | 31.933% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.2% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 75.781% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 96.219% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -34.617% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -246.365% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -2337.369% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 78.009% |
| GB Sciences, Inc. | 1.74 Million USD | 72.287% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 363.473% |
| HST Global, Inc. | 96.79 Thousand USD | -400.276% |
| CSL Limited | 10.52 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -134.817% |
| Halberd Corporation | 144.72 Thousand USD | -234.597% |
| Enzolytics Inc. | 981.65 Thousand USD | 50.672% |
| Agentix Corp. | 37.63 Thousand USD | -1186.79% |
| Resverlogix Corp. | 6.45 Million USD | 92.494% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 171.942% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.024% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.03% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 93.152% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 82.123% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 105.478% |
| AVAX Technologies, Inc. | -5.9 Million USD | 108.203% |
| Zenith Capital Corp. | 10.06 Thousand USD | -4711.526% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.046% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -141.594% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 79.706% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -194.35% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 2743.476% |
| Kadimastem Ltd | -253.1 Thousand USD | 291.319% |
| Helix BioMedix, Inc. | -2.57 Million USD | 118.841% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 97.612% |
| BioStem Technologies, Inc. | 4.47 Million USD | 89.172% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -140.607% |
| LadRx Corporation | -2.03 Million USD | 123.778% |
| Cell Source, Inc. | 9.23 Million USD | 94.755% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 23.763% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 23.763% |
| NovAccess Global Inc. | 2.17 Million USD | 77.772% |
| Affymax, Inc. | -5.59 Million USD | 108.652% |
| Itoco Inc. | 228.3 Thousand USD | -112.099% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -256.082% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 90.231% |
| CytoDyn Inc. | 20.26 Million USD | 97.61% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 74942.658% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 5324.582% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 93.716% |
| SYBLEU INC | 473.71 Thousand USD | -2.22% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 89.136% |
| International Stem Cell Corporation | 2.59 Million USD | 81.304% |
| Bioxytran, Inc. | 1.89 Million USD | 74.5% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -675.851% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 77.797% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 85.899% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 94.338% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 37.325% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 138.739% |
| Neutra Corp. | 52.18 Thousand USD | -827.879% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 119.455% |
| PureTech Health plc | -167.19 Million USD | 100.29% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 297.72% |
| IXICO plc | -4.44 Million USD | 110.895% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 96.337% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.117% |
| CSL Limited | 10.52 Billion USD | 99.995% |
| Cellectis S.A. | -43.81 Million USD | 101.105% |